India’s Glenmark to study potential COVID-19 drug combination

BENGALURU (Reuters) – Glenmark Pharmaceuticals Ltd said on Tuesday it will begin a new clinical trial in India to test a combination of two anti-viral drugs – favipiravir and umifenovir – as a potential COVID-19 treatment.

The study will look to enroll 158 hospitalized patients of moderate COVID-19 in India, the company added.

Last month, Glenmark said it would conduct clinical trials in India of just favipiravir as a potential treatment for COVID-19.

Reporting by Sachin Ravikumar, Editing by Sherry Jacob-Phillips

View original article here Source

Recommended For You

About the Author: GetFit